Company intelligence / Profile preview
MingSight Pharmaceuticals
San Diego, California, United Statesmingsight.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
MingSight Pharmaceuticals develops next-generation selective protein kinase C beta inhibitors. Its lead candidate MS‑553 has shown promising proof-of-mechanism data with strong efficacy and safety signals in ongoing Phase I/II trials targeting chronic lymphocytic leukemia/small lymphocytic lymphoma and diabetic macular edema. The compound aims to address shortcomings of previous pan-PKC inhibitors by improving selectivity, safety profile, and pharmacokinetics. Early results have demonstrated significant activity where prior approaches failed.[3][4]
- Therapeutic areas
- OphthalmologyOncologyEndocrinologyHematology
- Modalities
- Small molecules (selective PKCβ inhibitors)[1][2][4]Potential involvement with monoclonal antibodies (patents filed), but main clinical focus on small molecules[2]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Kaitai Capital led recent financing round; collaboration with Jiangsu MingSight Relin Pharmaceutical for China-based development/trials.[3][5]
Beyond the preview
Go deeper on MingSight Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MingSight Pharmaceuticals.